[Alemtuzumab in chronic lymphocytic leukemia treatment: retrospective analysis of outcome according to cytogenetics]

[Guest guest]

[Alemtuzumab in chronic lymphocytic leukemia treatment: retrospective analysis

of outcome according to cytogenetics]

M Doubek, A Jungova, M Brejcha, A Panovska, Y Brychtova, Z Pospisil, J Mayer,

and CELL, The CzEch Leukemia Study Group--for Life

Vnitr Lek, June 1, 2009; 55(6): 549-54.

Interní hematoonkologicá klinika Lékarské fakulty MU a FN Brno.

mdoubek@...

Alemtuzumab in chronic lymphocytic leukemia treatment: retrospective analysis of

outcome according to cytogenetics Summary: Alemtuzumab is effective in B-cell

chronic lymphocytic leukemia (CLL) with 17p deletion, which responds poorly to

chemotherapeutic agents. Our retrospective study evaluated the benefit of

alemtuzumab monotherapy in unselected patients with advanced CLL, categorized by

cytogenetic profile. Data were collected from 74 consecutive who had received

alemtuzumab. Median of previous therapies was 2. The incidence of cytogenetic

abnormalities was: trisomy 12, 10%; 13q deletion, 13%; 11q deletion 25%; 17p

deletion, 26%; none of these, 26%. The overall response rate was 65% (11%

complete remission, 54% partial remission) in the whole cohort. From start of

alemtuzumab therapy, median progression-free survival was 217 days, median time

to alternative treatment was 287 days, and median overall survival was 999 days

in the total cohort, respectively. Alemtuzumab was effective across all

cytogenetic categories evaluated. There were no statistically significant

differences between subgroups in the level of efficacy.

PMID: 19662885

----------

No virus found in this outgoing message.

Checked by AVG - www.avg.com

Version: 8.5.409 / Virus Database: 270.13.74/2339 - Release Date: 09/01/09

06:52:00